29 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 1669

Boan Biotech Announces 2022 Financial Results, Showing Accelerated Innovation and Strong 225% Revenue Growth

YANTAI, CHINA – Media OutReach – 28 March 2023 – Boan Biotech (6955.HK) announced its 2022 financial results and recent business developments on March 27, 2023.

2022 business highlights

  • Record high in revenue: In 2022, Boan Biotech’s revenue was approximately RMB 516 million, representing a strong growth of 225% from 2021, mainly attributable to the fast sales growth of Boyounuo® and the successful launch of Boyoubei® at the end of last year; its gross profit was approximately RMB 354 million, representing an even stronger growth of 233% from 2021, with a gross margin higher than that in 2021.
  • Fast progress in R&D: Boyoubei, the first denosumab biosimilar in the world developed by the company, was launched; 1 drug candidate entered the Biological License Application (BLA) stage, 2 saw significant progress with their Phase 3 clinical trials (including BA5101, the world’s first dulaglutide biosimilar to enter Phase 3 clinical trials), and 5 innovative antibodies as drug candidates entered Phase 1 clinical trials.
  • A new journey in the capital market: Boan Biotech was listed on the Main Board of the Hong Kong Stock Exchange (HKEX) on December 30, 2022, and was included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect on March 13, 2023.

Eye-catching performance of two marketed products

Boan Biotech’s first drug Boyounuo (bevacizumab injection, a biosimilar to Avastin®) is used for the treatment of multiple cancers. Sales grew rapidly immediately after it was launched in China in May 2021. Its first full-year sales were approximately RMB 515 million in 2022, which was a remarkable performance. Two new indications (ovarian cancer and cervical cancer) were also added for the drug last year, to further expand its patient base. Today, all the five indications of Boyounuo are on the 2022 National Reimbursement Drug List (NRDL).

Boyoubei (denosumab injection, a biosimilar to Prolia®), the company’s second product, was launched in China for the treatment of osteoporosis in November 2022. This is the world’s first marketed denosumab biosimilar. In addition to China, the company is also developing the product in Europe and the U.S., with a plan to market it globally.

Thanks to the strong sales performance of Boyounuo and the company’s well-established commercial capabilities, Boyoubei quickly achieved a number of business milestones in a shorter period of time after its approval. In December 2022, the drug was granted a code for reimbursement by the government’s health insurance system. In January 2023, the company granted CP Qingdao, a subsidiary of Sino Biopharm, the exclusive right to commercialize Boyoubei in the Chinese mainland, to put the product on the fast track for commercial success.

A fast growing pipeline with multiple first movers

Boan Biotech is able to innovate efficiently, and all of its products are in-house developed. The company has three platforms for innovation: the Human Antibody Transgenic Mouse and Phage Display Platform, the Bispecific T-cell Engager Platform, and the Antibody-drug Conjugate (ADC) Platform. On these platforms, Boan Biotech has built a strong portfolio, which includes 2 commercial products, 7 investigational antibodies, and 4 biosimilar candidates. Since 2022, the company has made remarkable progress in the development of multiple investigational drugs.

3 biosimilar candidates to be commercialized: BA1102 (denosumab injection, a biosimilar to Xgeva®), the BLA of which has been accepted in China, and which is also being developed in Europe and the U.S.; and BA5101 (dulaglutide injection, a biosimilar to Trulicity®) and BA9101 (aflibercept intravitreous injection, a biosimilar to Eylea®), both of which are in Phase 3 clinical trials in China, with BA5101 being the world’s first dulaglutide biosimilar to enter Phase 3 clinical trials.

5 innovative antibodies under Phase 1 clinical trials: BA1106, a non-IL-2 blocking anti-CD25 antibody, which is the first innovative anti-CD25 antibody for the treatment of solid tumors to enter the clinical trial stage in China; BA2101, an anti-IL-4Rα monoclonal antibody, which is the first long-acting anti-IL-4Rα antibody in the autoimmunity therapeutic area to enter the clinical trial stage in China; BA1105, an ADCC-enhanced anti-Claudin 18.2 antibody, which is expected to become the best-in-class targeted therapy for the treatment of metastatic pancreatic cancer, advanced gastric cancer, and adenocarcinoma of the esophagogastric junction; BA1201, an anti-PD-L1/TGF-β bispecific antibody fusion protein; and BA1301, an injectable ADC targeting Claudin18.2.

Boan Biotech keeps a balance between “the value of innovation” and “commercial visibility”. While striving to build a differentiated portfolio, it is also speeding up R&D to gain a first-mover advantage. Many of the above-mentioned drug candidates are ahead of competition in terms of development progress. They set a clear path for the company’s commercialization efforts in the short term, and also lay a solid foundation for its long-term sustainable growth.

Strong commercial capabilities ensure successful new product launch

Boan Biotech is one of a few Chinese biopharmaceutical companies operating across the value chain of the industry from research and development to manufacturing and commercialization. The company’s highly integrated and coordinated internal operation system enabled it to be able to “produce blood” on its own in a shorter period of time. Besides, the company also has strong commercial capabilities, which ensure the successful launch of its investigational drugs later on.

Boan Biotech has been reinforcing its commercial capabilities by leveraging its own professional marketing team and its strategic partners. On the one hand, the company has established an extensive distribution network covering more than 1,300 hospitals and other institutions nationwide. On the other hand, it is joining hands with strong industry partners such as AstraZeneca, CP Qingdao, and OcuMension and leveraging their resources to unleash the clinical value and market potential of its products. In addition, the company has subsidiaries in the U.S. and Singapore, and also has a growing international R&D team and business development team to support the rapid growth of its business.

Moreover, to further support commercialization, in 2022, Boan Biotech ramped up the effort to increase production capacity, and also embraced digital management and upgraded production processes in an effort to reduce cost and increase efficiency. Currently, the company has a total capacity of 8,000 liters for commercial production and 1,700 liters for pilot production. It is also building two 3*2,000-liter lines for commercial production and two 2*500-liter lines for pilot production.

Jiang Hua, Chairlady and Chief Executive Officer of Boan Biotech, said: “It’s very exciting and encouraging to see remarkable breakthroughs and accomplishments of our company in 2022 despite various challenges posed by COVID-19 and a changing industry landscape. Looking forward, we expect 2023 to be a banner year for the revenue growth of our commercial products and a transformative year for accelerating our pipeline of innovative antibodies. Next, we will further accelerate the clinical development of our key products around the world, expand our portfolio of innovative antibodies, beef up our manufacturing and commercial capabilities, and build partnerships, as we want to meet patient needs, reward our shareholders, and give back to communities with more high-quality innovations.”

Hashtag: #BoanBiotech

The issuer is solely responsible for the content of this announcement.

About Boan Biotech

Boan Biotech (6955.HK) is a fully-integrated biopharmaceutical company developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company discovers antibodies on three technology platforms: Human Antibody Transgenic Mouse and Phage Display Technology Platform, Bispecific T-cell Engager Technology Platform, and ADC Technology Platform. Boan Biotech operates across the entire value chain of the industry from antibody discovery, cell line development, upstream and downstream process development, analytical and bio-analytical method development, and technology transfer to pilot and commercial production.

Boan Biotech’s portfolio currently includes two commercialized products, multiple investigational antibodies protected for their international intellectual property rights, and a number of biosimilar candidates. In addition to China, the company is also developing biopharmaceutical products in overseas markets, including the U.S. and the EU. Due to the company’s differentiated product portfolio and well-established commercialization capabilities, Boan Biotech has built a comprehensive industry value chain operation system covering “R&D – production – commercialization”, laying a solid foundation for long-term and high-quality development.

Cambodian PM to Issue Benefit Cards to Dolphin Zone Villagers

Cambodian PM Plans to Issue Benefit Cards to Dolphin Zone Villagers
The protected dolphins in Cambodia (photo: WWF - Cambodia)

Cambodian Prime Minister Hun Sen urged government authorities during a meeting last Friday to issue ID Poor cards to people living in the Irrawaddy dolphin protected area, as an incentive to cease fishing.

SSY announces 2022 annual results

Net profit up approx. 43% to HK$1,123 million; Final dividend HK$0.08/share Revenue sets record high; Seize new development opportunities

Result summary:

  • Total revenue HK$6,434 million, representing a growth of approx. 20%;
  • Net profit HK$1,123 million, representing a growth of approx. 43%;
  • The Board resolved to pay final dividend of HK$0.08 /share

HONG KONG SAR – Media OutReach – 28 March 2023 – SSY Group Limited (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the annual results of the Company for the year ended 31 December 2022 (“2022” or “the year”).

During the year, the Group achieved a revenue of HK$6,434 million, representing an increase of approximately 20% with the gross profit margin decreased by 3.8 percentage point to 55.4%. The Group achieved net profits of HK$1,123 million, representing an increase of approximately 43% as compared with last year. In response to the recurring novel coronavirus epidemic outbreak and the further implementation of reform to the National Centralised Medicines Procurement, the Group strengthened the market expansion of dominant preparations and key preparation types. The Group also persistently optimised its product mix, leading to a new progress in market shares and sales volume. The Group made full use of market access opportunities from national centralized medicines procurement, and quickly introduced more solid preparations and small liquid injection products into the market. The bulk pharmaceuticals business achieved scale operation for the first year, and the production industrial chain was further extended. The Group performed a continuously and consistently favourable performance in overall operation. Revenue of the Group has set another record high.

The Board of directors resolved to pay a final dividend of HK$0.08 per share for year 2022, together with interim dividend HK$0.06 per share, total dividend for full year of 2022 will be HK$0.14 per share, representing an increase of approximately 17% from last year.

The Group continued to increase its market shares of the intravenous infusion solution business and solidify its leading position in the market. In 2022, sales volume of infusion solution reached 1,580 million bottles (bags), representing an increase of approximately 16% as compared to last year. Ampoule injections product line has become increasingly rich in varieties with its production and sales gradually scaled up. During the year, sales volume of ampoule products was approximately 160 million, representing an increase of approximately 49% as compared to last year. Solid preparations business has sped up the upgrading of its product mix and production and sales scale, In line with the national and local centralised medicines procurement policies, the Group made coordinated efforts to secure market supply of tender-awarded products, achieved revenue of HK$346 million, representing an increase of approximately 62% as compared to last year. Bulk pharmaceuticals business continuous optimised its production process, the premium production capacities were realised. As a vertical integration, the Group acquired Cangzhou Lingang Youyi Chemical Co., Ltd. near the beginning of the year, significantly improving the coordination between upstream and downstream entities of the industrial chain. During the year, revenue of bulk pharmaceuticals was HK$1,360 million, representing an increase of approximately 155% as compared to last year. Production and sales of medical materials were steady, recorded a revenue of HK$172 million from external sales during the year. Exports of preparations to foreign countries had a positive trend. The export of preparations recorded a revenue of approximately HK$149 million, representing an increase of approximately 78% as compared to last year.

By using market demands as the guide and adhering to the principle of “combination of generic and innovative drugs”, the Group maintained its intensity in research and development investment. The Group also made coordinated efforts to push forward the research and development progress of featured generic drugs, bulk pharmaceuticals, innovative drugs, medical materials as well as product types under consistency evaluation. In 2022, research and development of featured generic drugs of the Group ranked top of the peers in the PRC in terms of the number of approvals and applications, a total of 37 national production approvals were obtained for various products, among which four product types including Pentoxifylline Injection, Blonanserin Tablets, Azithromycin for Suspension and Peritoneal Dialysis Solution (Lactate-G1.5%) were the first passing such evaluation in the PRC. In addition, nine bulk pharmaceuticals such as Pentoxifylline and Levornidazole were approved for production, ensuring the supply of bulk pharmaceuticals for preparation production effectively. At present, the Group has products of 38 types with 50 specifications passed the consistency evaluation or been regarded as passing the consistency evaluation. The Group achieved positive progress in the Phase I clinical trial of type I chemical innovative drug NP-01 project. At the same time, type I chemical innovative drug ADN-9 aims to commence Phase I clinical trial in the second half of 2023. The Group has achieved new results in innovation platform construction and talent cultivation, and joined hands with the scientific research team from China Pharmaceutical University, experts from Shenyang Pharmaceutical University and other institutions to carry out research and development of small molecular compounds as well as specialised first generic drugs, pushing the Group’s research & development and innovation towards mid-to-high end.

Looking forward to 2023, following the lifting of the pandemic restrictions, there will be gradual improvement in the economic situation. The Group will continue to enhance technology innovation as well as the resilience of the industrial chain and supply chain, with an aim to facilitate the dual circulation of domestic and international markets, so that the high quality and high-speed development of the Group will be maintained. In 2023, sales volume in the business plan of intravenous infusion is targeted at no less than 1,800 million bottles (bags), representing an increase of approximately over 14% as compared to last year. The Group has started new construction of two production lines of upright soft bag in a timely manner in view of market demands, with additional production capacity of 600 million bags annually. By adopting a vast amount of new technologies and facilities, the production lines will turn to be the most advanced model of intelligent manufacturing and digital transformation in the industry. The Group will improve the sales proportion of therapeutic infusion products, at the same time make full use of its innovation achievements in the research and development of solid preparations, ampoule injections, lyophilized powder and other types of products. The Group will put its full effort in implementation the tender-awarded products under the seventh round of National Centralised Medicines Procurement, and seize the market opportunities arising from the eighth round of National Centralised Medicines Procurement. The Group will make efforts to strengthen and expand its bulk pharmaceuticals business, and make a greater contribution to the development of the Group. With a focus on the key target of an annual production and sales volume of 7,000 tonnes of caffeine in 2023, the Group will devote more efforts to explore domestic customers while stabilising the overseas customer base. In terms of research and development of new product, efforts will be made to achieve new breakthroughs in accelerating development of specialised generic drugs and innovative drugs. The Group will continue to proactively push forward the upgrade of Jiangsu Best New Medical Material listing to the A-share market of the Beijing Stock Exchange and spinoff listing of bulk pharmaceuticals in the PRC. At the same time, the Group will proactively seek opportunities of acquisition and investment in the pharmaceutical industry.

Mr. Qu Jiguang, Chairman and CEO of SSY said, “By leveraging on its own advantages, the Group will seize new opportunities in the industry development, maintain the resilience and vitality of innovative development, and strive for promoting high quality development of the Group. We firmly believe that, by virtue of our scale, quality, management and brand advantages accumulated in the industry over the years and our continuous stimulation of innovation momentum, we will definitely bring satisfactory returns to our investors with a more solid development performance.”

Hashtag: #SSY

The issuer is solely responsible for the content of this announcement.

About SSY Group Limited

SSY Group Limited is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005. The Group is principally engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, including finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The manufacturing plants of the Group locates in Hebei Province and Jiangsu Province in China, and its pharmaceutical products has leading position in the high-end hospital market in China.

Myanmar Army Leader Calls for Decisive Action to Crush Foes

Myanmar Army Leader Calls for Decisive Action to Crush Foes
Senior. Gen. Min Aung Hlaing, head of the military council, inspects a parade, marking Myanmar's 78th Armed Forces in Naypyitaw, Myanmar. ( Photo : AP )

BANGKOK (AP) — As Myanmar’s military put on an annual show of strength Monday, its top leader told its assembled ranks they need to take decisive action against those fighting army rule of the country.

Air Purifiers Sell Out in Vientiane as Residents Express Concerns Over Pollution

Vientiane Sees Surge in Air Purifier Demand Due to Poor Air Quality
Vientiane Capital engulfed with a thick haze of PM 2.5 (photo: Houmphet Manisouk)

Residents of Vientiane have been rushing to purchase air purifiers from local electronics shops due to high levels of PM2.5 dust particles affecting the capital’s air quality since last week.

Young Malaysian small business owners drive up tech focus

  • Malaysian small businesses are more confident in their business and the economy
  • Young small business owners are driving a greater focus on technology and innovation
  • The increasing attention on innovation and technology will support long term growth

KUALA LUMPUR, MALAYSIA – Media OutReach – 28 March 2023 – Malaysian small businesses are upbeat about their business and the economy. Meanwhile, young business owners are driving an increasing focus on technology and innovation by local small businesses. These are some of the findings from a new regional survey by one of the world’s largest professional accounting associations.

CPA Australia’s latest Asia-Pacific Small Business Survey shows 72.2 per cent of Malaysian small businesses expect to grow in 2023, compared to 54.6 per cent that grew last year.

This trend is being driven by an improving economy and more small businesses grasping the benefits of digital technology including e-commerce, supported by new digital payment opportunities.

“An increasing focus on e-commerce will position many Malaysian small businesses for future growth,” Malaysia Division President Surin Segar FCPA (Aust.) said.

The survey found 63.9 per cent earned more than 10 per cent of their revenue from online sales in 2022. Consistent with this, almost three-quarters (72.9 per cent) received more than 10 per cent of their sales through digital payment technologies such as GrabPay.

Small businesses are achieving strong returns from technology spending, with 53 per cent reporting this investment in 2022 improved their profitability. The financial gains available are helping drive the adoption of new technology.

“Nearly all Malaysian small businesses use social media. Businesses were more likely to invest in mobile phone applications than any other technology.”

Over a third (34.1 per cent) said they will introduce a new product, process or service to Malaysia or the world in 2023, up from 25.3 per cent last year.

“Small businesses are ready to innovate in 2023. This innovative culture should support long-term growth and improve the competitiveness of Malaysia’s small business sector.

“The appetite to innovate is hugely encouraging. The high percentage of Malaysians under 40 running small businesses is a contributing factor.”

Younger business owners surveyed were more likely to run businesses that are growing, creating jobs, innovating, using emerging technologies and exporting.

“To harness the entrepreneurial spirit of Malaysia’s many young small business owners, we want to see policymakers incentivise them to access professional advice.

“The increased use of technology raises cyber risks all businesses need to be aware of. Almost half (48 per cent) of small businesses reviewed their cybersecurity in the last six months. While this result was up from 2021, we want to see that figure climb higher.”

CPA Australia’s Malaysia market summary

Hashtag: #CPAAustralia

The issuer is solely responsible for the content of this announcement.

About CPA Australia

CPA Australia is one of the largest professional accounting bodies in the world, with more than 170,000 members in over 100 countries and regions, including more than 10,500 members in Malaysia. CPA Australia has been operating in Malaysia since 1956 and opened our Malaysian office in 1994. Our core services include education, training, technical support and advocacy. CPA Australia provides thought leadership on local, national and international issues affecting the accounting profession and public interest. We engage with governments, regulators and industries to advocate policies that stimulate sustainable economic growth and have positive business and public outcomes. Find out more at

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kornit Digital Ltd. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – KRNT

New York, US – Newsfile Corp. – March 27, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kornit Digital Ltd., (NASDAQ: KRNT) between February 17, 2021 and July 5, 2022, both dates inclusive (the “Class Period”), of the important April 17, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Kornit securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Kornit class action, go to https://rosenlegal.com/submit-form/?case_id=12250 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 17, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Kornit and its senior executives knew or, at a minimum, recklessly disregarded, that the Company’s digital printing business was beset by significant quality control problems and deficient customer service; (2) as a result, Kornit was more vulnerable to pressure from competitors than it had represented and lacked the competitive advantages it touted to investors; (3) as a result, problems and deficiencies caused Kornit to lose market share to competitors, which led to a decline in the Company’s revenues, as Kornit’s dissatisfied customers sought out alternative options for their digital printing needs; and (4) to the extent that the Company purported to warn of risks regarding quality and customer service issues as well as increased competition, Kornit failed to disclose that such risks had already materialized. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Kornit class action, go to https://rosenlegal.com/submit-form/?case_id=12250 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fidelity National Information Services, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – FIS

New York, US – Newsfile Corp. – March 27, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Fidelity National Information Services, Inc. (NYSE: FIS) between February 9, 2021 and February 10, 2023, both dates inclusive (the “Class Period”), of the important May 5, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Fidelity National securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Fidelity National class action, go to https://rosenlegal.com/submit-form/?case_id=12773 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the integration of Worldpay with the Fidelity National Merchant Solutions business was not ahead of schedule; (2) the integration of Worldpay with the Fidelity National Merchant Solutions business was not successfully completed during the Class Period; (3) the increases in revenue synergies were not driven by the Worldpay integration; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fidelity National class action, go to https://rosenlegal.com/submit-form/?case_id=12773 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.